Concepedia

Tim Demuth

TD

Statistics

Publications

32

Citations

3.2K

H-Index

24

Active since

2000

Affiliations

Translational Genomics Research Institute(Current)

Novartis (Switzerland)

Princess Margaret Cancer Centre

Massachusetts General Hospital

Merck & Co., Inc., Rahway, NJ, USA (United States)

Tim Demuth is an author at Translational Genomics Research Institute specializing in medicine, radiation oncology, and tumor biology.

Top concepts

Publications per year

2000–2017

32

Publications

32

Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors

Ian E. Krop, Tim Demuth, Tina Guthrie et al. · Journal of Clinical Oncology · 2012 · 314 citations · Full text

MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts

N.V. Rajeshkumar, Elizabeth De Oliveira, Niki A. Ottenhof et al. · Clinical Cancer Research · 2011 · 274 citations · Full text

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors

Suzanne Leijen, Robin M.J.M. van Geel, Anna C. Pavlick et al. · Journal of Clinical Oncology · 2016 · 263 citations · Full text

A Mathematical Model of Glioblastoma Tumor Spheroid Invasion in a Three-Dimensional In Vitro Experiment

Andrew M. Stein, Tim Demuth, David L. Mobley et al. · Biophysical Journal · 2006 · 243 citations · Full text

, , +7

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic <i>BRAF</i> -Mutant Colorectal Cancer

Robin M.J.M. van Geel, Josep Tabernero, Élena Elez et al. · Cancer Discovery · 2017 · 226 citations · Full text

1–5 of 32